Effects of dalfampridine: A Synthesis of Findings from 27 Studies

  1. Home
  2. Effects of dalfampridine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dalfampridine: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dalfampridine: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Dalfampridine is a potassium channel blocker that has been used to improve walking ability in people with multiple sclerosis (MS). 5 , 27 , 1 , 14 , 18 , 6 , 25 , 7 , 20 , 4 , 19 , , 24 , 3 , 23 , 2 , 15 , 22 , 12 , 17 , 26 , 10 , 11 , Some studies suggest that dalfampridine may also improve fatigue in MS patients. 16 , 8 On the other hand, dalfampridine can increase the risk of seizures. , 13 It is also important to be cautious when taking dalfampridine if you have kidney problems. 7 , 15 , 12 5 This potassium channel blocker has shown to improve walking ability in patients with Parkinson’s disease-related gait dysfunction. 16 In patients with multiple sclerosis, dalfampridine has been approved to improve walking ability, and the drug may also improve cognition, fatigue, and mood. 8 In combination with multicomponent physical therapy, dalfampridine has shown to improve gait speed in people with MS. 21 Dalfampridine can cause status epilepticus, especially in patients with a history of seizures or depression. 13 A case report showed that dalfampridine can cause a seizure even in a patient without a history of seizures or renal disease. 23 A pilot study on patients with spinal muscular atrophy showed that dalfampridine did not have a statistically significant positive effect on their walking ability, but it may enhance neuronal activity. 2

Benefits and Risks

Benefit Summary

Dalfampridine can improve walking speed in MS patients. Some studies suggest it might also help improve fatigue.

Risk Summary

Dalfampridine can increase the risk of seizures. People with kidney problems need to be cautious when taking this medication.

Comparison between Studies

Commonalities

Many studies have shown that dalfampridine can improve walking speed in MS patients.

Differences

While some studies indicate that dalfampridine may also improve fatigue, others have not confirmed this effect. 16 , 8 The effects of dalfampridine can vary from person to person, and it may not be effective for everyone.

Consistency and Inconsistencies of Results

While there is consistent evidence regarding the effectiveness of dalfampridine, further research is needed to understand the extent of its effectiveness and to identify patients who are more likely to benefit from this drug.

Practical Considerations

Dalfampridine can improve walking speed in MS patients, but its effectiveness varies. It can also increase the risk of seizures. It is crucial to take this medication under the guidance of a healthcare professional and exercise caution.

Limitations of Current Research

There is still a lot we don't know about the effects of dalfampridine. More research is needed, especially on its long-term effects and side effects.

Future Research Directions

To further understand the effects of dalfampridine, we need long-term clinical trials and research aimed at identifying individuals who are more likely to benefit or not benefit from this drug.

Conclusion

Dalfampridine is a medication that can improve walking speed in MS patients. However, its effectiveness is individual-specific, and it carries a risk of seizures. When taking dalfampridine, follow your doctor's instructions and be cautious.

Literature analysis of 27 papers
Positive Content
26
Neutral Content
0
Negative Content
1
Article Type
5
1
0
8
25
2.

Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients.

Author: ChiribogaClaudia A, MarraJonathan, LaMarcaNicole M, YoungSally Dunaway, WeimerLouis H, LevinBruce, McCabeBrian

Improved motor function

This pilot study investigated the tolerability and efficacy of dalfampridine (4-AP) in adults with spinal muscular atrophy (SMA). Dalfampridine was safe and well tolerated, but no significant improvements in walking ability were observed. Larger studies are needed to confirm these findings.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

4.

Long-term effects of dalfampridine in patients with multiple sclerosis.

Author: RuckT, BittnerS, SimonO J, GöbelK, WiendlH, SchillingM, MeuthS G

Improve cognitive function
Improve mobility

This study examines the short- and long-term effects of dalfampridine, a medication used to treat impaired mobility in patients with multiple sclerosis, on motor and cognitive function over 9-12 months.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial.

Author: LucaCorneliu C, NadayilGloria, DongChuanhui, NahabFatta B, Field-FoteEdelle, SingerCarlos

Gait improvement

Dalfampridine, a potassium channel blocker, was investigated as a potential treatment for gait dysfunction in Parkinson's disease (PD). The study aimed to evaluate the safety and efficacy of dalfampridine for improving walking in people with PD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Author: GoodmanAndrew D, BethouxFrancois, BrownTheodore R, SchapiroRandall T, CohenRon, MarinucciLawrence N, HenneyHerbert R, BlightAndrew R,

Improved walking speed

This study reports the results of two Phase 3 trials (MS-F203 and MS-F204) that investigated the efficacy of dalfampridine extended release tablets in patients with multiple sclerosis (MS). The drug improved walking speed compared to placebo.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.

Author: SamaraEmil, WinklePeter, PardoPatricia, HenneyHerbert R, WaySusan L, BrownEppie, LeeAngela, BlightAndrew R

Arthralgia
Dizziness
Headache

Dalfampridine extended release tablets (D-ER) are used to improve walking in patients with multiple sclerosis (MS). This study evaluated the pharmacokinetics of D-ER in healthy subjects and subjects with mild and moderate renal impairment. D-ER exposure was significantly higher in subjects with renal impairment compared to healthy subjects, suggesting that lower doses may be required in patients with renal impairment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Clinical overview of the seizure risk of dalfampridine.

Author: HautSheryl R, BienenE Jay, MillerAaron

Improved walking
Seizure risk

Dalfampridine extended release tablets are approved for the improvement of walking in patients with multiple sclerosis (MS). Its mechanism of action and narrow therapeutic range necessitate the evaluation of seizure risk in treated patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials.

Author: ZhangEnyao, TianXin, LiRuoming, ChenChaoyang, LiMin, MaLingyun, WeiRan, ZhouYing, CuiYimin

MS symptom relief

This meta-analysis assessed the safety and benefits of dalfampridine, a treatment for multiple sclerosis (MS) symptoms, compared to placebo. The analysis summarized data from previously published clinical randomized controlled studies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.

Author: CameronMichelle H, FitzpatrickMary, OversShannon, MurchisonCharles, ManningJane, WhithamRuth

Self-perceived walking improvement
Walking endurance improvement

Dalfampridine extended release (ER) was associated with short-term improvements in walking speed and community participation and sustained improvements in walking endurance and self-perceived impact of MS on walking for one year.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Refractory Convulsive Status Epilepticus Provoked by Intoxication with Dalfampridine in a Patient with Multiple Sclerosis and Depression Disorder: A Case Report and Literature Review.

Author: MaghbooliMehdi, JourahmadZahra, GolizadehMehrdad

Epilepsy

Overdose of dalfampridine, a drug used to improve motor function in multiple sclerosis patients, can lead to seizures. This case report describes a patient who overdosed on dalfampridine and experienced seizures that were difficult to control. The patient recovered after intensive treatment in the intensive care unit.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Emerging oral agents for multiple sclerosis.

Author: FoxEdward J

Improved adherence
Improved efficacy
Tolerable side effects
Long-term safety unknown

This article reviews the mechanisms of action, efficacy, and safety and tolerability of 4 emerging oral therapies for MS: cladribine, laquinimod, fingolimod, and dalfampridine. Cladribine, laquinimod, and fingolimod have demonstrated impressive efficacy in terms of clinical outcomes, such as annualized relapse rate and change in disability scores, as well as magnetic resonance imaging variables.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Dalfampridine: a new agent for symptomatic management of multiple sclerosis.

Author: McDonaldSarah, ClementsJennifer N

Improved walking
Seizures

Dalfampridine is a new drug that blocks potassium channels on demyelinated neurons in patients with multiple sclerosis. It improves walking speed and is well tolerated with the most frequent adverse events reported being insomnia, dizziness, headache, nausea, and weakness.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.

Author: TricheElizabeth W, RuizJennifer A, OlsonKayla M, LoAlbert C

Improved walking
Possible cognitive benefits
Possible fatigue benefits
Possible mood benefits

Dalfampridine-extended release (D-ER) has been approved for improving walking in patients with multiple sclerosis. The study aims to investigate the impact of D-ER on cognition, depression, mood, and fatigue, examining the association between D-ER and improved walking speed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Dalfampridine benefits ambulation but not cognition in multiple sclerosis.

Author: SatchidanandNikhil, DrakeAllison, SmerbeckA, HojnackiDavid, KolbChanna, PatrickKara, Weinstock-GuttmanBianca, MotlRobert, BenedictRalph Hb

ambulation improvement
cognitive improvement
MS symptoms

This study discusses the potential benefits of dalfampridine, an FDA-approved medication for impaired ambulation in multiple sclerosis (MS), for patients with cognitive impairment. Dalfampridine's effects on saltatory conduction and the association between cognitive and motor function suggest that it may be beneficial for cognitive impairment in MS patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Author: ApplebeeAngela, GoodmanAndrew D, MayadevAngeli S, BethouxFrancois, GoldmanMyla D, KlinglerMichael, BlightAndrew R, CarrazanaEnrique J

Distance walked
Walking speed

A subgroup analysis of 153 patients with multiple sclerosis (MS) from a randomized, placebo-controlled, double-blind study found that dalfampridine extended-release (ER) 10 mg BID, but not 5 mg BID, was associated with statistically significant and clinically meaningful improvements in walking speed and distance walked compared to placebo. The study suggests that dalfampridine ER 10 mg BID is effective for improving walking in people with MS.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

<i>Case Report:</i> Combining Dalfampridine with Multicomponent Exercise and Gait Training in a Person with Multiple Sclerosis.

Author: PlummerPrudence, BohlingCorinne J, NicklesL Ellese, WilliamsAlexis A, ThomasAmy, Markovic-PleseSilva, GiesserBarbara

Gait speed improvement
MS treatment
Small improvements

This case report describes a successful combination of dalfampridine extended release (D-ER) and multicomponent physical therapy for improving gait speed in a patient with multiple sclerosis. The patient experienced only small improvements with D-ER alone, but the combination therapy significantly improved gait speed.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

24.

Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.

Author: WellerD, LörinczL, SutterT, ReuterK, LinnebankM, WellerM, ZörnerB, FilliL

Improved walking ability

Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) can improve walking ability in some PwMS. This study examined the effects of PR-fampridine on gait kinetics in PwMS. The findings suggest that PR-fampridine can induce changes in gait kinetics in a subgroup of PwMS, potentially contributing to improved walking performance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

25.

Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Author: RabadiMeheroz H, KreymborgKimberly, VincentAndrea S

Improved motor function
Improved walking endurance
Improved walking speed
Adverse effects

Dalfampridine improved walking speed and endurance in veterans with multiple sclerosis (MS) with limited ambulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

26.

Guidelines and best practices for appropriate use of dalfampridine in managed care populations.

Author: MiravalleAugusto A

Improved walking
Reduced costs

Dalfampridine's ability to improve walking in patients with multiple sclerosis may complement the effects of disease-modifying treatments (DMTs) and potentially reduce the direct and indirect costs associated with MS care.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

27.

Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.

Author: BergerJoseph R

Improved walking
Reduced relapses
Slowed disease progression

Dalfampridine, a potassium channel blocker, can improve walking ability in patients with multiple sclerosis and potentially complement the effects of disease-modifying treatments (DMTs).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.